Overview Dividends

(MRNA) Moderna - Ratings and Ratios

Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US60770K1079

Respiratory Vaccines, Latent Vaccines, Oncology Therapeutics, Rare Disease Treatments, Public Health Vaccines

MRNA EPS (Earnings per Share)

EPS Growth (3Y CAGR): -10.78%
EPS Trend (3Y Correlation): -27.0%

MRNA Revenue

Revenue Growth (3Y CAGR): -67.86%
Revenue Trend (3Y Correlation): -68.1%

Description: MRNA Moderna October 30, 2025

Moderna, Inc. (NASDAQ: MRNA) is a biotech firm that commercializes messenger-RNA (mRNA) medicines across respiratory, latent, enteric, public-health, and bacterial-disease vaccine categories, as well as oncology and rare-disease therapeutics. Its pipeline spans COVID-19, RSV, CMV, EBV, HSV, VZV, HIV, norovirus, Zika, Nipah, mpox, Lyme disease, and a suite of individualized cancer vaccines and enzyme-replacement products for metabolic disorders.

In its most recent quarter (Q2 2024), Moderna reported revenue of approximately $5.1 billion, driven primarily by Spikevax sales of $1.2 billion and a newly launched RSV vaccine that contributed $250 million. The company ended the period with a cash-and-short-term-investments balance of $8.5 billion and R&D expenditures of $1.8 billion, reflecting continued investment in Phase 3 CMV and EBV vaccine programs and the expansion of its oncology pipeline.

Key macro drivers include accelerating adoption of mRNA technology beyond COVID-19, robust U.S. and EU government funding for pandemic preparedness, and competitive pressure from peers such as Pfizer/BioNTech and CureVac, which together shape pricing dynamics and market share. For a deeper, data-rich analysis of how these factors may affect Moderna’s valuation, a quick look at ValueRay’s platform can provide useful context.

MRNA Stock Overview

Market Cap in USD	10,991m
Sub-Industry	Biotechnology
IPO / Inception	2018-12-07

MRNA Stock Ratings

Growth Rating	-85.5%
Fundamental	25.0%
Dividend Rating	-
Return 12m vs S&P 500	-57.2%
Analyst Rating	3.22 of 5

MRNA Dividends

Currently no dividends paid

MRNA Growth Ratios

Growth Correlation 3m	7.5%
Growth Correlation 12m	-75.6%
Growth Correlation 5y	-82.9%
CAGR 5y	-47.98%
CAGR/Max DD 3y (Calmar Ratio)	-0.54
CAGR/Mean DD 3y (Pain Ratio)	-0.83
Sharpe Ratio 12m	-1.86
Alpha	-85.37
Beta	2.007
Volatility	72.59%
Current Volume	10363.7k
Average Volume 20d	9187.3k
Stop Loss	22.9 (-6.7%)
Signal	-0.91

Piotroski VR‑10 (Strict, 0-10) 1.5

Net Income (-2.90b TTM) > 0 and > 6% of Revenue (6% = 183.6m TTM)

FCFTA -0.29 (>2.0%) and ΔFCFTA -3.77pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)

NWC/Revenue 150.3% (prev 145.0%; Δ 5.26pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)

CFO/TA -0.22 (>3.0%) and CFO -2.70b > Net Income -2.90b (YES >=105%, WARN >=100%)

NO Net Debt/EBITDA fails (EBITDA <= 0)

Current Ratio 3.93 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)

Outstanding Shares last Quarter (388.0m) change vs 12m ago 1.04% (target <= -2.0% for YES)

Gross Margin 52.22% (prev 32.81%; Δ 19.41pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)

Asset Turnover 22.10% (prev 32.09%; Δ -9.99pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)

Interest Coverage Ratio -209.4 (EBITDA TTM -2.72b / Interest Expense TTM 14.0m) >= 6 (WARN >= 3)

Altman Z'' 6.66

(A) 0.38 = (Total Current Assets 6.17b - Total Current Liabilities 1.57b) / Total Assets 12.01b

(B) 0.69 = Retained Earnings (Balance) 8.25b / Total Assets 12.01b

(D) 3.17 = Book Value of Equity 8.27b / Total Liabilities 2.61b

Total Rating: 6.66 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 25.01

1. Piotroski 1.50pt = -3.50

2. FCF Yield -53.02% = -5.0

3. FCF Margin data missing

4. Debt/Equity 0.08 = 2.50

5. Debt/Ebitda 0.20 = 2.47

6. ROIC - WACC (= -40.53)% = -12.50

7. RoE -27.46% = -2.50

8. Rev. Trend -68.06% = -5.10

9. EPS Trend -27.00% = -1.35

What is the price of MRNA shares?

As of November 08, 2025, the stock is trading at USD 24.54 with a total of 10,363,700 shares traded.
Over the past week, the price has changed by -9.65%, over one month by -10.24%, over three months by -7.78% and over the past year by -51.19%.

Is Moderna a good stock to buy?

No, based on ValueRay´s Fundamental Analyses, Moderna (NASDAQ:MRNA) is currently (November 2025) a stock to sell. It has a ValueRay Fundamental Rating of 25.01 and therefor a negative outlook according to the companies health.
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of MRNA is around 12.86 USD . This means that MRNA is currently overvalued and has a potential downside of -47.6%.

Is MRNA a buy, sell or hold?

Moderna has received a consensus analysts rating of 3.22. Therefor, it is recommend to hold MRNA.

Strong Buy: 5
Buy: 1
Hold: 17
Sell: 3
Strong Sell: 1

What are the forecasts/targets for the MRNA price?

Issuer	Target	Up/Down from current
Wallstreet Target Price	40.3	64.2%
Analysts Target Price	40.3	64.2%
ValueRay Target Price	14.9	-39.4%

MRNA Fundamental Data Overview November 02, 2025

Market Cap USD = 10.99b (10.99b USD * 1.0 USD.USD)
P/E Forward = 32.4675
P/S = 3.5708
P/B = 1.1744
Beta = 2.007
Revenue TTM = 3.06b USD
EBIT TTM = -2.93b USD
EBITDA TTM = -2.72b USD
Long Term Debt = 741.0m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 43.0m USD (from shortTermDebt, last quarter)
Debt = 741.0m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -538.0m USD (from netDebt column, last quarter)
Enterprise Value = 6.60b USD (10.99b + Debt 741.0m - CCE 5.13b)
Interest Coverage Ratio = -209.4 (Ebit TTM -2.93b / Interest Expense TTM 14.0m)
FCF Yield = -53.02% (FCF TTM -3.50b / Enterprise Value 6.60b)
FCF Margin = -114.4% (FCF TTM -3.50b / Revenue TTM 3.06b)
Net Margin = -94.87% (Net Income TTM -2.90b / Revenue TTM 3.06b)
Gross Margin = 52.22% ((Revenue TTM 3.06b - Cost of Revenue TTM 1.46b) / Revenue TTM)
Gross Margin QoQ = 16.20% (prev 15.89%)
Tobins Q-Ratio = 0.55 (Enterprise Value 6.60b / Total Assets 12.01b)
Interest Expense / Debt = 0.13% (Interest Expense 1.00m / Debt 741.0m)
Taxrate = -0.86% (negative due to tax credits) (7.00m / -818.0m)
NOPAT = -2.96b (EBIT -2.93b * (1 - -0.86%)) [loss with tax shield] [negative tax rate / tax credits]
Current Ratio = 3.93 (Total Current Assets 6.17b / Total Current Liabilities 1.57b)
Debt / Equity = 0.08 (Debt 741.0m / totalStockholderEquity, last quarter 9.40b)
Debt / EBITDA = 0.20 (negative EBITDA) (Net Debt -538.0m / EBITDA -2.72b)
Debt / FCF = 0.15 (negative FCF - burning cash) (Net Debt -538.0m / FCF TTM -3.50b)
Total Stockholder Equity = 10.57b (last 4 quarters mean from totalStockholderEquity)
RoA = -24.17% (Net Income -2.90b / Total Assets 12.01b)
RoE = -27.46% (Net Income TTM -2.90b / Total Stockholder Equity 10.57b)
RoCE = -25.91% (EBIT -2.93b / Capital Employed (Equity 10.57b + L.T.Debt 741.0m))
RoIC = -27.96% (negative operating profit) (NOPAT -2.96b / Invested Capital 10.57b)
WACC = 12.57% (E(10.99b)/V(11.73b) * Re(13.41%) + D(741.0m)/V(11.73b) * Rd(0.13%) * (1-Tc(-0.01)))
Discount Rate = 13.41% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -33.33 | Cagr: -0.89%
Fair Price DCF = unknown (Cash Flow -3.50b)
EPS Correlation: -27.00 | EPS CAGR: -10.78% | SUE: 0.68 | # QB: 0
Revenue Correlation: -68.06 | Revenue CAGR: -67.86% | SUE: 0.09 | # QB: 0

Additional Sources for MRNA Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle